Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiagnoCure dips as US FDA delays panel meeting for review of prostate cancer test

This article was originally published in Clinica

Executive Summary

Shares in cancer diagnostics specialist DiagnoCure dropped 13% yesterday after the US FDA postponed a review of its Progensa PCA3 test for prostate cancer. The FDA notified DiagnoCure's commercial partner Gen-Probe that its immunology panel will not be reviewing the product on 14 October as previously planned, as it needs more time to analyse and respond to the information provided by Gen-Probe in its premarket approval (PMA) application.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel